Select Language
B7-H3
B7-H3 Overview
| English Name | CD276 antigen | Approved Drugs | 0 |
| Drugs in Clinical Trials | 54 | Target Synonym | B7 homolog 3，PSEC0249，UNQ309/PRO352，B7-H3，CD276 antigen，B7H3，CD276，CD276 Molecule，Costimulatory Molecule，4Ig-B7-H3，B7RP-2 |
| Highest Development Stage | NDA/BLA | ||
| English Name | CD276 antigen |
| Target Synonym | B7 homolog 3，PSEC0249，UNQ309/PRO352，B7-H3，CD276 antigen，B7H3，CD276，CD276 Molecule，Costimulatory Molecule，4Ig-B7-H3，B7RP-2 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 54 |
| Highest Development Stage | NDA/BLA |
B7-H3 Product List
- Product Category
Protein (6)Beads (1)Antibody (1)
- Product Status
Launched (8)
- Species
Human (6)Rabbit (1)Cynomolgus (1)
- Tag
Fc Tag (1)His Tag (2)His Tag & Avi Tag (2)Fc Tag & Avi Tag (1)- (2)
- Conjugate
Unconjugated (3)Biotin-labeled (3)- (1)PE Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT B73-H5253 |  Human | HEK293 | Human B7-H3 / CD276 Protein, Fc Tag (MALS verified) |  |  |  |  Add to Cart |
HOT B73-H52E2 | Human | HEK293 | Human B7-H3 / CD276 Protein, His Tag, low endotoxin (MALS verified) |  | | | Add to Cart |
HOT B73-H82E6 | Human | HEK293 | Biotinylated Human B7-H3 / CD276 Protein, Avitag™,His Tag |  | | | Add to Cart |
HOT B73-H82F5 | Human | HEK293 | Biotinylated Human B7-H3 / CD276 Protein, Fc,Avitag™ (MALS verified) |  | | | Add to Cart |
HOT MBS-K040 | Human | - | Human B7-H3(4Ig)-coupled Magnetic Beads | Add to Cart | |||
B73-HP2H3 | Human | HEK293 | PE-Labeled Human B7-H3 / CD276 Protein, His TagStar Staining | Add to Cart | |||
B73-C82E3 |  Cynomolgus | HEK293 | Biotinylated Cynomolgus B7-H3 / CD276 Protein, His,Avitag™ |  | | | Add to Cart |
HGS-S609 |  Rabbit | - | Recombinant Monoclonal Anti-B7-H3 Antibody, Rabbit (7A1) | Add to Cart |
Total: 8
- 1
B7-H3 Background
B7 homolog 3 (B7-H3), a member of the immunoglobulin superfamily, is also known CD276, which contains two Ig-like C2-type (immunoglobulin-like) domains and two Ig-like V-type (immunoglobulin-like) domains. B7-H3 may participate in the regulation of T-cell-mediated immune response. B7-H3 also plays a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. Furthermore, B7-H3 is involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. It could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy.
B7-H3 Synonyms
B7-H3,CD276,B7 homolog 3
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ifinatamab deruxtecan | I-DXd; MK-2400; DS-7300a; DS-7300; MABX-9001a | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Esophageal Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Neoplasm Metastasis | Details |
| YL-201 | YL-201; YL201 | Phase 3 Clinical | MediLink Therapeutics Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Nasopharyngeal Carcinoma | Details |
| HS-20093 | GSK-5764227; GSK’227; HS-20093; HS20093; GSK5764227 | Phase 3 Clinical | Shanghai Hansoh Biomedical Co Ltd | Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Osteosarcoma; Sarcoma; Soft Tissue Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Ovarian Neoplasms | Details |
| B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) | Phase 2 Clinical | Boyuan Runsheng Pharma (Hangzhou) Co Ltd | Solid tumours; Glioblastoma | Details | |
| Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Sarcoma, Synovial; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Breast Neoplasms; Neurofibrosarcoma; Prostatic Neoplasms; Neuroblastoma; Sarcoma; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Colonic Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
| Vobramitamab duocarmazine | MGC-018 | Phase 2 Clinical | Macrogenics Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Carcinoma, Renal Cell; Hormone-Resistant Prostate Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Pancreatic Ductal; Laryngeal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| GD2/B7H3 CAR T-cell therapy(Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Desmoplastic Small Round Cell Tumor; Neuroblastoma | Details | |
| DB-1419 | DB-1419 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours | Details |
| IBI129 | IBI-129; IBI129 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| 7MW-3711 | 7MW3711; 7-MW-3711 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
| IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| MHB088C | MHB-088C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
| DB-1311 | DB-1311; BNT-324 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
| IBB-0979 | IBB0979; IBB-0979 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| ILB-3101 | ILB-3101 | Phase 2 Clinical | Innolake Biopharm (Hangzhou) Co Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
| Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
| CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Phase 2 Clinical | Shenzhen University General Hospital | Pancreatic Neoplasms | Details |
| Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics Inc | Wilms Tumor; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Urethral Neoplasms; Sarcoma, Ewing; Osteosarcoma; Prostatic Neoplasms; Neuroblastoma; Urinary Bladder Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Abdominal Neoplasms; Carcinoma, Renal Cell; Desmoplastic Small Round Cell Tumor; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours | Details |
| SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Sarcoma, Synovial; Neoplasms, Germ Cell and Embryonal; Diffuse Intrinsic Pontine Glioma; Sarcoma, Clear Cell; Osteosarcoma; Retinoblastoma; Neuroblastoma; Neurofibrosarcoma; Sarcoma, Ewing; Sarcoma; Solid tumours; Central Nervous System Neoplasms; Wilms Tumor; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Diffuse midline glioma; Desmoplastic Small Round Cell Tumor; Rhabdomyosarcoma | Details | |
| 124I-omburtamab | 124I-8H9; 124I-8H9-(B7-H3) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Y-Mabs Therapeutics Inc | Brain Neoplasms; Glioma | Details |
| Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
| CAR.B7-H3 T cells | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Ovarian Neoplasms; Glioblastoma; Neuroblastoma; Peritoneal Neoplasms; Carcinoma, Pancreatic Ductal; Fallopian Tube Neoplasms | Details | |
| second generation anti-CD276 CAR T-cell therapy (Seattle Children's Hospital/Cureworks) | Phase 1 Clinical | Seattle Children'S Hospital | Rhabdomyosarcoma; Solid tumours; Hepatoblastoma; Neoplasms; Wilms Tumor; Neuroblastoma; Osteosarcoma; Retinoblastoma; Sarcoma; Sarcoma, Ewing; Carcinoma, Embryonal; Melanoma | Details | |
| BCB-276 | BRAINCHILD-03; SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital, BrainChild Bio Inc | Sarcoma; Melanoma; Neoplasms, Germ Cell and Embryonal; Choroid Plexus Neoplasms; Glioma; Neuroectodermal Tumors, Primitive; Diffuse Intrinsic Pontine Glioma; Neuroblastoma; Retinoblastoma; Neurofibrosarcoma; Sarcoma, Ewing; Sarcoma, Clear Cell; Osteosarcoma; Teratoma; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Rhabdoid Tumor; Hepatoblastoma; Desmoplastic Small Round Cell Tumor; Carcinoma; Diffuse midline glioma; Rhabdomyosarcoma; Ependymoma; Medulloblastoma; Solid tumours | Details |
| CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
| KT-095 | KT-095 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Solid tumours | Details |
| EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
| GTB-5550 | GTB-5550; B7H3 TriKE™; cam1615B7H3; GTB-5550 TriKE™ | Phase 1 Clinical | University Of Minnesota | Solid tumours | Details |
| WL276 CAR-T Cell Therapy(Immunochina Medical Science & Technology) | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Glioblastoma | Details | |
| SYS-6043 | SYS6043; SYS-6043 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| SKB-500 | SKB500; SKB-500 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| CAR.B7-H3 T cells (Unc Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Glioblastoma | Details | |
| SDTM-001 | SDTM-001; SDTM001 | Phase 1 Clinical | Sidet Biopharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| [68Ga] B7H3 Affibody-BCH(Beijing Cancer Hospital) | Phase 1 Clinical | Beijing Cancer Hospital | Neoplasms | Details | |
| BGB-C354 | BGB-C354 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours; Lung Neoplasms; Gastrointestinal Neoplasms | Details |
| IBI-3001 | IBI-3001; IBI3001 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| MGC-026 | MGC026; MGC-026 | Phase 1 Clinical | Macrogenics Inc | Prostatic Neoplasms, Castration-Resistant; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms | Details |
| Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Solid tumours; Neoplasms; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
| Autologous CAR-T Cells Targeting B7-H3(Unc Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Bellicum Pharmaceuticals Inc, Unc Lineberger Comprehensive Cancer Center | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms | Details | |
| BB-1712 | BB-1712 | Phase 1 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Solid tumours | Details |
| QH-104 | QH-104 | Phase 1 Clinical | Beijing Qinghui Liannuo Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours; Peritoneal Neoplasms; Glioma | Details |
| MT-027 | MT-027 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Solid tumours; Central Nervous System Neoplasms; Mesothelioma; Brain Neoplasms; Glioma; Nervous System Neoplasms; Pleural Neoplasms; Pleural Effusion, Malignant | Details |
| UTAA-06 | UTAA-06; UTAA06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Leukemia, Myeloid, Acute | Details |
| B7-H3 CAR T-cell therapy(Stanford University) | B7-H3CART | Phase 1 Clinical | Stanford University | Ovarian Neoplasms; Neuroblastoma; Osteosarcoma; Sarcoma; Nervous System Diseases | Details |
| TX-103 | TX-103 | Phase 1 Clinical | Fuzhou Tcelltech Biological Science and Technology Co Ltd | Solid tumours; Glioma | Details |
| EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
| B7-H3-targeting CAR-T cell therapy | Phase 1 Clinical | Beijing Tiantan Hospital, Capital Medical University | Glioblastoma | Details | |
| BAT-8009 | BAT8009; BAT-8009 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| TAA-06 | TAA06-UCAR-γδT; TAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma | Details |
| XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
| anti-B7-H3 CAR T-cell therapy (Soochow T-Maximun Biotechnology/Second Affiliated Hospital of Soochow University) | Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details | |
| TX-103-CAR-T | TX-103-CAR-T | Clinical | Union Hospital Affiliated To Fujian Medical University | Head and Neck Neoplasms; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Glioma | Details |
- Overview
- Product List
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland